Vita 34 AG Logo

Vita 34 AG

A cell bank storing umbilical cord stem cells as biological insurance for families' future health.

V3V | F

Overview

Corporate Details

ISIN(s):
DE000A0BL849
LEI:
529900OEWA4GSZEZ4P40
Country:
Germany
Address:
Perlickstr. 5, 04103 Leipzig
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Vita 34 AG is a leading European biotechnology company and full-service cell bank specializing in cryopreservation. The company's core services include the collection, processing, and long-term storage of stem cells derived from umbilical cord blood and tissue. These potent hematopoietic and mesenchymal stem cells are preserved for potential future use in regenerative medicine and the treatment of numerous diseases. Established in 1997 as Europe's first private cord blood bank, Vita 34 has consistently been a pioneer in the field. Following a business combination with Polski Bank Komórek Macierzystych S.A., the company has expanded its European leadership and now operates as part of the FamiCord Group, providing families with a form of biological insurance for future health.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-16 18:53
M&A Activity
FamiCord AG: Polski Bank Komorek Macierzystych sp. z o. o. is to acquire 100 % …
English 6.0 KB
2025-08-27 07:00
Earnings Release
FamiCord AG significantly increases revenue and earnings in the first half of 2…
English 19.8 KB
2025-08-27 00:00
Interim Report
Half-yearly financial report 2025
English 358.1 KB
2025-08-20 13:23
Report Publication Announcement
English 3.9 KB
2025-06-10 00:00
Annual / Quarterly Financial Statement
Jahresabschluss zum Geschäftsjahr vom 01.01.2024 bis zum 31.12.2024
German 348.2 KB
2025-05-29 16:19
M&A Activity
FamiCord AG acquires majority stake in Narodni Centrum Pupecnikove Krve and Rod…
English 6.6 KB
2025-05-28 07:00
Earnings Release
FamiCord AG starts 2025 financial year with accelerated growth and increases pr…
English 16.6 KB
2025-05-28 00:00
Quarterly Report
Q1 statement / Q1 financial report 2025
English 675.0 KB
2025-05-19 00:00
Annual Report
Konzernabschluss zum Geschäftsjahr vom 01.01.2024 bis zum 31.12.2024
German 1.6 MB
2025-05-15 15:05
Pre-Annual General Meeting Information
FamiCord AG: Bekanntmachung der Einberufung zur Hauptversammlung am 25.06.2025 …
German 88.4 KB
2025-04-30 14:09
Earnings Release
FamiCord AG continues growth course in 2024 after strong year-end business and …
English 18.6 KB
2025-04-30 00:00
Annual Report
Annual financial report 2024
English 6.9 MB
2025-04-23 16:18
Report Publication Announcement
English 4.4 KB
2025-04-23 00:00
Report Publication Announcement
Hinweis auf Jahresfinanzbericht vom 01.01.2024 bis zum 31.12.2024
German 5.7 KB
2025-04-23 00:00
Report Publication Announcement
Hinweis auf Konzernabschluss vom 01.01.2024 bis zum 31.12.2024
German 5.7 KB

Automate Your Workflow. Get a real-time feed of all Vita 34 AG filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Vita 34 AG via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2023-12-11 AOC Health GmbH Close relation Other None 6,572,680.40 EUR
2023-12-11 Baran, Jakub Julian Other Buy None 99,998.80 EUR
2022-09-28 Dr. Granderath, Rat und Vermögen GmbH Close relation Buy None 21,557.28 EUR
2022-06-02 Dr. Granderath, Rat und Vermögen GmbH Close relation Buy None 33,000.00 EUR
2022-06-02 Schweppe, Thomas Supervisory board Other None N/A
2021-11-18 Lorenzen, Hans-Jochen Supervisory board Sell None 180,625.00 EUR
2021-11-10 Project Mill Gesellschaft für interdisziplinären Know-how-Transfer GmbH Close relation Other None 36,146.25 EUR
2021-11-09 Zeitfracht GmbH & Co. KGaA Close relation Sell None 35,525.00 EUR
2021-11-09 von Blücher, Dietmar Board Buy None 28,820.00 EUR
2021-11-09 von Blücher, Dietmar Board Buy None 14,400.00 EUR

Peer Companies

Company Country Ticker View
Eisai Co., Ltd. Logo
A global, research-based pharmaceutical firm that develops and markets prescription and OTC drugs.
Japan 4523
Elicera Therapeutics AB Logo
Develops CAR T-cell & oncolytic virus therapies for cancer, enhanced by its iTANK platform.
Sweden ELIC
Ellen AB Logo
Develops research-based probiotic and prebiotic products for women's intimate health and pH balance.
Sweden ELN
Enlivex Therapeutics Ltd. Logo
Developing cell therapy to restore immune balance for inflammatory diseases like sepsis.
Israel ENLV
Enorama Pharma AB Logo
Develops & makes consumer nicotine products & medicated gums, offering private label solutions.
Sweden ERMA
Develops novel therapeutics and APIs for oncology, inflammation, and respiratory diseases.
South Korea 183490
Enzymatica AB Logo
Develops medical devices with patented enzyme technology to treat upper respiratory infections.
Sweden ENZY
Developing alopecia therapies, skin regeneration products, and preclinical CRO services.
South Korea 446440
EQL Pharma AB Logo
Develops and sells cost-efficient niche generic medicines for the Nordic healthcare market.
Sweden EQL
ERYTECH Pharma S.A. Logo
Developing phage therapies to combat antibiotic-resistant bacterial infections.
France ERYP

Talk to a Data Expert

Have a question? We'll get back to you promptly.